Open AccessNeoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?
Author(s) -
Laura Biganzoli,
Amelia McCartney
Publication year - 2020
Publication title -
chinese clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.733
H-Index - 22
eISSN - 2304-3873
pISSN - 2304-3865
DOI - 10.21037/cco.2019.12.06
Subject(s) - medicine , paclitaxel , breast cancer , oncology , nab paclitaxel , neoadjuvant therapy , cancer
In the treatment of early breast cancer, the addition of a sequential taxane following an anthracycline-based regimen has improved patient outcomes (1), with studies suggesting that weekly solvent-based paclitaxel given after an anthracycline regimen significantly reduces the risk of relapse (2,3).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom